SCHEMBL4300290

SCHEMBL4300290

O=C(O)C(Cl)Oc1ccc(Br)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.66
PPARG P37231 5/20 0.51
PPARA Q07869 5/20 0.51
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
SRD5A2 P31213 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
CYP1A2 P05177 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL367795 0.82 PPARG (0.56) PPARGPPARA
SCHEMBL101519 0.81 PPARG (0.46) LDHAPPARGPPARAALDH1A1KMT2A
SCHEMBL9721990 0.80 PPARG (0.51) LDHAPPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL1324245 0.80 PPARG (0.51) LDHAPPARGPPARAALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL11631504 0.80 PPARG (0.54) PPARGPPARA
SCHEMBL13603761 0.79 LDHA (1.00) LDHAPPARGPPARAKDM4EALDH1A1
SCHEMBL28131536 0.79 PPARG (0.45) PPARGPPARAALDH1A1KMT2AMEN1
Phosphine SCHEMBL28858272 0.79 PPARG (0.45) PPARGPPARAALDH1A1SMN1; SMN2KMT2A
SCHEMBL11841309 0.78 LDHA (0.49) LDHAPPARGPPARAKDM4EALDH1A1
SCHEMBL10717267 0.77 RXRA (0.44) PPARGPPARAKDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394799-B2 Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2013-03-12 US disclosed
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT HIF1AN, HIF1A, VHL LDHA 605/4885PPARG 292/4885PPARA 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.